DPP4 and type 2 diabetes mellitus: DPP-4 inhibitors including linagliptin, sitagliptin, and vildagliptin have been shown to enhance β cell function of T2D patients as assessed by physiological parameters, and the effect is mainly attributed to upregulation of circulating GLP-138–40.